Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M

Pacira BioSciences, Inc.

2023-Q1 EPS reported -$0.43 revenue$160,341,000

Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.
EXPAREL net product sales $130.4M, avg daily volumes up 6%, offset by 340B pricing; ZILRETTA $24.3M; iovera° $4.0M.
Adjusted EBITDA $41.9M vs $53.8M in Q1 2022; non-GAAP net income $24.3M ($0.53 diluted share).
FDA accepted sNDA for EXPAREL lower-extremity nerve blocks; PDUFA date Nov 13, 2023.
Repaid $287.5M Term Loan B using $150M new Term Loan A and cash; appointed Christopher Young Chief Manufacturing Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported the first quarter of 2023 results: revenue $160.3 million, net income $19.5 million, EPS $0.43 per share (basic and diluted). Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: $160.3 million
Net income: $19.5 million
EPS: $0.43 per share (basic and diluted)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023 Financial Highlights • Total revenues of $160.3 million • Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for iovera° • Net loss of $19.5 million, or $0.43 per share (basic and diluted) •

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.